Shanghai RAAS Blood Products Co., Ltd.

Equities

002252

CNE100000C31

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-06-23 pm EDT 5-day change 1st Jan Change
7.5 CNY -2.98% Intraday chart for Shanghai RAAS Blood Products Co., Ltd. -0.40% -6.25%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Haier Gets Regulatory Nod to Buy Controlling Stake in RAAS Blood Products MT
RAAS Blood Products Renews Cooperation Deal With Spain's Grifols MT
Haiyingkang Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. from Grifols, S.A.. CI
Shanghai RAAS Blood Products Co., Ltd. Implements 2023 Final Profit Distribution Plan of A Shares, Payable on 05 June 2024 CI
Shanghai Raas Blood Products Co., Ltd. Approves 2023 Profit Distribution Plan CI
GRIFOLS CEO SAYS CAN CONFIRM SHANGHAI RAAS TRANSACTION WILL CLO… RE
Shanghai RAAS Blood Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
RAAS Blood Products' 2023 Profit Falls 5% Despite 21% Revenue Growth MT
Shanghai RAAS Blood Products Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake RE
RAAS Blood Products Gets Regulatory Nod to Trial Drug for Bleeding Disorders MT
Grifols says due diligence was carried out on Shanghai RAAS stake sale RE
Grifols' shares tumble as restructuring costs hit annual profit RE
S&P Maintains Grifols' Rating, Stable Outlook Amid Expected Deleveraging MT
S&P keeps Grifols at 'B+', sees leverage decreasing in 2024 RE
ECB probes banks over exposure to Spanish drugmaker Grifols: sources RE
ECB sounds out lenders on exposure to Spanish drugmaker Grifols - sources RE
The Ibex-35 rebounds without leaving the range of the last month and a half. RE
Grifols Wins Assurance from Haier for Shanghai RAAS Stake Deal MT
Grifols says Haier Group still OK to buy stake in Shanghai RAAS RE
GRIFOLS: HAIER GROUP'S CHAIRWOMAN SAYS COMPANY CONTINUES TO WOR… RE
Grifols shares suffer worst week on record after short-seller report RE
Grifols foresees no problems in the sale of its stake in China despite Gotham City's report RE
Grifols to Finalize $1.8 Billion Shanghai RAAS Stake Sale as Planned in H1 MT
Grifols sees no impact from Gotham report on China stake sale RE
Chart Shanghai RAAS Blood Products Co., Ltd.
More charts
Shanghai RAAS Blood Products Co., Ltd. specializes in the research, development and manufacturing of plasma-derived therapeutics. The group's products include human albumin, immunoglobulin and coagulation factors (thrombin, fibrinogen, prothrombin and fibrin). China accounts for 96.6% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
7.5 CNY
Average target price
6.55 CNY
Spread / Average Target
-12.67%
Consensus
  1. Stock Market
  2. Equities
  3. 002252 Stock
  4. News Shanghai RAAS Blood Products Co., Ltd.
  5. RAAS Blood Products Gets Regulatory Nod to Trial Drug for Bleeding Disorders